Peter C. Farrell is the founder and former CEO of ResMed Inc., a leading company in the healthcare sector focused on developing solutions for people with sleep apnea and chronic obstructive pulmonary disease. Under his leadership from 1989 until January...

Peter C. Farrell is the founder and former CEO of ResMed Inc., a leading company in the healthcare sector focused on developing solutions for people with sleep apnea and chronic obstructive pulmonary disease. Under his leadership from 1989 until January 2023, ResMed has grown significantly, becoming a key player in the healthcare technology industry. He transitioned to the role of chair emeritus after appointing Michael ‘Mick’ Farrell as the new chair of the board, highlighting his lasting impact on the company. Interestingly, Peter has consistently driven ResMed’s performance metrics including revenue growth and operational efficiency, demonstrating a commitment to aligning executive compensation with company success. His compensation has remained steady, peaking at $2.2 million in 2017, reflecting the company's ups and downs. Furthermore, Peter’s insider trading activity shows fluctuations in his wealth tied to ResMed, with stock values reaching over $268 million in late 2020. This indicates a significant stake in the company and suggests a strong belief in its future. Peter is a recognized figure in the healthcare industry, known for his strategic guidance and vision, and remains influential as a board member after a remarkable leadership tenure.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other ResMed CEOs

R

Peter C. Farrell

Founder and Ex-CEO of ResMed

Field of Expertise

Healthcare & Life Sciences - Healthcare

Sector of Economy

Healthcare

CEO of ResMed for

33 years 6 months (Jul 1989 - Jan 2023)

Previous Experience

Founder and CEO of ResMed

Rivals

Competitors/colleagues of Peter C. Farrell

M

August J. Troendle

Founder and CEO of Medpace Holdings, Inc.

2023 Compensation

Stock

$0.00

Salary

$825.00K

Bonus

$814.42K

Other

$17.33K

Total Holdings

$1.76B

E

Mark J. Tarr

CEO of Encompass Health Corporation

2023 Compensation

Stock

$3.28M

Salary

$1.05M

Bonus

$0.00

Other

$66.92K

Total Holdings

$51.02M

H

Andrew Dudum

Founder and CEO of Hims & Hers Health

2023 Compensation

Stock

$6.54M

Salary

$625.00K

Bonus

$1.14M

Other

$167.60K

Total Holdings

$9.65M

Holdings

See how much did Peter C. Farrell make over time.

Peter C. Farrell's insider trading history shows great fluctuation in his holdings in ResMed. His wealth tied to ResMed grew significantly, peaking at over $268 million in December 2020. This was during a time when his leadership helped propel the...

Peter C. Farrell's insider trading history shows great fluctuation in his holdings in ResMed. His wealth tied to ResMed grew significantly, peaking at over $268 million in December 2020. This was during a time when his leadership helped propel the company to prolonged success in the healthcare technology market. The values fluctuated from around $30 million in late 2019 to impressive increases over 2020, before stabilizing considerably. By 2022, his stock holdings indicated a decrease to about $40 million but remained substantial, evidencing his continued investment in ResMed's future. This pattern showcases not only his substantial financial commitment but also a confidence in the company's directions amidst market changes, illustrating a strategic approach to personal and professional investments in healthcare.

Total Stock Sold

$136.40M

RMD

$136.40M

2,337,766 RMD shares

What if they kept their stock?

If Peter C. Farrell didn't sell their stock, today they would have:
Extra RMD2,337,766 shares worth $375.94M.
This is 175.62% and $239.54M more than what they got when they sold the stock.

Charitable Transactions

RMD

2,419,225 shares

RMD

Recent Charitable Transactions

RMD

68,200 shares

RMD

May 15, 2024

Charity

RMD

4,550 shares

RMD

Oct 31, 2022

Charity

RMD

36,670 shares

RMD

Aug 13, 2021

Charity

RMD

$1.60M

RMD at $115.40/share

Dec 13, 2018

Charity

RMD

$4.41M

RMD at $84.96/share

Dec 14, 2017

Charity

RMD

$249.99K

RMD at $84.80/share

Nov 28, 2017

Charity

Insider Trading

See recent insider trades of Peter C. Farrell.

RMD

$455.42K

RMD at $227.71/share

Mar 5, 2025

Sale

RMD

$968.44K

RMD at $242.11/share

Feb 5, 2025

Sale

RMD

$461.98K

RMD at $230.99/share

Jan 2, 2025

Sale

RMD

$491.30K

RMD at $245.65/share

Dec 4, 2024

Sale

RMD

542 shares

RMD

Nov 20, 2024

Received

RMD

$497.48K

RMD at $248.74/share

Nov 6, 2024

Sale

RMD

$474.40K

RMD at $237.20/share

Oct 2, 2024

Sale

RMD

$479.80K

RMD at $239.90/share

Sep 4, 2024

Sale

RMD

68,200 shares

RMD

May 15, 2024

Charity

RMD

$4.94M

RMD at $209.92/share

May 3, 2023

Sale

Compensation History

See how much did Peter C. Farrell make over time.

In recent years, Peter C. Farrell's total compensation at ResMed has remained notable, consistently around $1.1 million annually since 2020. This includes a fixed salary of $800,000, bonuses based on performance targets, and vested stocks as part of a long-term incentive plan. In 2022, he received a bonus of $200,000 along with the value of vested stock totaling $250,000. His total compensation peaked at $2.2 million in 2017, largely due to a substantial stock vesting at that time, showing how closely his income is tied to the company's performance metrics like revenue growth and operational efficiency. The structured, performance-focused compensation reflects a commitment both to the company's growth and to aligning with shareholder interests.

Year

2022

Total Compensation

$1.35M

Salary

$800.00K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, aiming to attract and retain top executive talent while driving shareholder value.

Bonus

$200.00K

Board Justification

The bonus is based on the company's performance metrics including revenue growth and operational efficiency for the year 2022.

Other

$100.00K

Board Justification

Other compensation includes retirement contributions and health benefits provided to the CEO in 2022.

Restricted Stock

$250.00K(5K common stock)

Board Justification

5,000 shares of common stock vested in 2022 as part of the long-term incentive plan, based on performance criteria met during the vesting period.

Performance Metrics

Performance metrics include revenue growth, earnings before interest and taxes (EBIT), and operational efficiency targets.

Other ResMed CEOs

Here are other CEOs of ResMed

Michael J. Farrell

CEO of ResMed

July 2019 - Present